Piper Sandler analyst Edward Tenthoff reiterated a Buy rating on Tempest Therapeutics (TPST – Research Report) today and set a price target of $8.00. The company’s shares closed yesterday at $3.74.
According to TipRanks, Tenthoff is a 4-star analyst with an average return of 4.0% and a 38.15% success rate. Tenthoff covers the Healthcare sector, focusing on stocks such as Alnylam Pharma, Arrowhead Pharmaceuticals, and Mesoblast.
Tempest Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $20.75, implying a 454.81% upside from current levels. In a report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $47.00 price target.
See the top stocks recommended by analysts >>
TPST market cap is currently $74.49M and has a P/E ratio of -1.53.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Tempest Therapeutics (TPST) Company Description:
Tempest Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapeutics to treat cancer.
Read More on TPST:
- Tempest Reports Year End 2023 Financial Results and Provides Business Update
- Scotiabank starts Tempest at Outperform on liver cancer potential
- Tempest Therapeutics initiated with an Outperform at Scotiabank
- Tempest Therapeutics presents new data on TPST-1120 at SITC meeting
- Tempest Announces Upcoming Presentation of Preclinical Data for TPST-1120 in Renal Cell Carcinoma at the AACR Annual Meeting
